AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Innoviva, Inc.
Video analysis: INVA
All videosNo video analysis for this stock yet. Request one from our team.
News: INVA
Innoviva to Participate in Upcoming Investor Conferences
Innoviva, Inc. (NASDAQ: INVA) (âInnovivaâ or the âCompanyâ), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical
Hsbc Holdings PLC Buys Shares of 49,428 Innoviva, Inc. $INVA
Hsbc Holdings PLC acquired a new position in Innoviva, Inc. (NASDAQ: INVA) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 49,428 shares of the biotechnology company's stock, valued at approximately $843,000. Hsbc Holdings PLC owned 0.07% of Innoviva as of its most
Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company's infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics prod.
Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic
Innoviva is a company that is transitioning from a pure royalty-based business to a diversified healthcare company with commercial products and strategic assets. I have rated Innoviva as a buy with a probability-weighted fair value of $35.26 and a base case value of $36.92. This represents a 68.1% upside from here. GSK royalties have been a main source of revenue and are now under pressure. But new therapeutic products have been ramping up to close the gap left by royalties.
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
Innoviva (INVA) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.77 per share a year ago.
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2026, and highlighted select corporate progress and achievements. “Innoviva delivered an.
Supernus Pharmaceuticals Q2 Earnings Call Highlights
Supernus Pharmaceuticals NASDAQ: SUPN and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing 12-month net revenue as of June 30, 2026.
Dimensional Fund Advisors LP Acquires 76,026 Shares of Innoviva, Inc. $INVA
Dimensional Fund Advisors LP grew its holdings in shares of Innoviva, Inc. (NASDAQ: INVA) by 1.7% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 4,436,427 shares of the biotechnology company's stock after acquiring an additional 76,026 shares during the period. Dimensional Fund Advisors LP owned
